Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Paediatric high-grade glioma (excluding diffuse midline glioma), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No systemic therapy has improved survival in H3 G34-mutant or H3- and IDH-wildtype tumours.
How long to continue fusion or BRAF inhibitors in children who respond, and what happens on stopping.
Radiotherapy to the developing brain costs cognition and growth; avoiding it in infants depends on drugs that reach the brain.
Small numbers make randomised trials slow; international platform trials are the answer being tried.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
Hargrave and colleagues (JCO) report durable responses in the paediatric cohort.
Dabrafenib plus trametinib (paediatric high-grade glioma cohort 2023; tumour-agnostic approval for BRAF V600E solid tumours from age six).
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.